Clinical-Stage Companies / Anhui Zhifei Longcom Biologic Pharmacy

Anhui Zhifei Longcom Biologic Pharmacy

Pre-Approval PRO BETA

Total Trials

Phase 3

Phase 2

Recruiting

277

Score

Pipeline by Phase

Phase 3

Phase 2

Phase 1

Therapeutic Focus

Tuberculosis Latent Tuberculosis Infection COVID-19 Prevention of COVID-19 BCG

Clinical Trials (31)

NCT06747455 Phase 3 ACTIVE NOT RECRUITING

BCG for Therapeutic Use Phase Ⅲ Clinical Trial

Started: 4/8/2025

NCT05899179 Phase 3 COMPLETED

Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above

Started: 8/3/2023

NCT06524947 Phase 3 ACTIVE NOT RECRUITING

Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)

Started: 7/27/2024

NCT05642078 Phase 3 COMPLETED

Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine

Started: 2/18/2023

NCT06078423 Phase 3 COMPLETED

A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells)

Started: 10/19/2019

NCT05107375 Phase 3 COMPLETED

Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine

Started: 9/3/2021

NCT02795260 Phase 3 COMPLETED

Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)

Started: 5/1/2016

NCT01979900 Phase 3 COMPLETED

Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis

Started: 10/1/2013

NCT03027154 Phase 3 COMPLETED

Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen for Children

Started: 10/1/2016

NCT02623556 Phase 3 COMPLETED

Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen

Started: 12/1/2015

NCT05284812 Phase 2 SUSPENDED

A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)

Started: 2/10/2022

NCT05109598 Phase 2 COMPLETED

Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19） Vaccine (CHO Cell)

Started: 11/4/2021

NCT02336542 Phase 2 COMPLETED

Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

Started: 11/1/2014

NCT02389322 Phase 2 COMPLETED

Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65

Started: 3/1/2015

NCT02329730 Phase 2 COMPLETED

Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

Started: 2/1/2014

NCT06824519 Phase 1 RECRUITING

Clinical Trials of Quadrivalent Influenza Vaccine

Started: 5/8/2025

NCT06100653 Phase 1 COMPLETED

BCG for Therapeutic Use Phase I Clinical Trial

Started: 11/22/2023

NCT06975774 Phase 1 COMPLETED

Phase II Clinical Clical of the Pure Protein Derivatives of BCG

Started: 7/26/2023

NCT04538911 Phase 1 ACTIVE NOT RECRUITING

Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients

Started: 7/2/2021

NCT04563533 Phase 1 COMPLETED

Clinical Trial of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)

Started: 8/5/2020

NCT05205096 Phase 1 COMPLETED

Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac

Started: 11/10/2021

NCT05198063 Phase 1 COMPLETED

ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization

Started: 1/10/2022

NCT04563273 Phase 1 COMPLETED

Clinical Study of BCG Vaccine for Intradermal Injection

Started: 10/21/2020

NCT04961359 Phase 1 COMPLETED

Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)

Started: 7/3/2021

NCT05198102 Phase 1 COMPLETED

ZF2001 Booster Immunization Clinical Trials of 12 Months After the Completion of Basic Immunization

Started: 12/29/2021

NCT04239313 Phase 1 COMPLETED

A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02)

Started: 5/27/2020

NCT03026972 Phase 1 COMPLETED

A Phase ⅠStudy of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried

Started: 4/16/2018

NCT04593771 Phase 1 COMPLETED

Phase I Clinical Protocol of BCG-PPD in Healthy People

Started: 10/21/2020

NCT01999231 Phase 1 COMPLETED

Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10

Started: 9/1/2013

NCT05746611 Phase 4 COMPLETED

Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein

Started: 4/17/2023

NCT05680415 Phase 4 ACTIVE NOT RECRUITING

Clinical Trial of Mica

Started: 4/19/2023

Drug Candidates

BCG for Therapeutic Use BCG for Therapeutic Use ( BI SAI JI ) Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant (low dose) Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant placebo (low dose) Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant (high dose) Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant placebo (high dose) Influenza Vaccine (Split Virion), Inactivated, Quadrivalent BCG for therapeutic use Purified Protein Derivative of BCG（BCG-PPD） Recombinant Mycobacterium Tuberculosis Fusion Protein

Activity Status: Active

Last Trial Started: 5/8/2025

Last Trial Ended: 9/22/2025

Trials (12 months): 1

Completed Trials: 25

Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.